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1. Introduction
There are three types of autophagy, macroautophagy, microautophagy and chaperon-
mediated autophagy. Macroautophagy is the largest in terms of the scale, and often briefly 
referred to as autophagy as here. In recent years, researches in the field of autophagy have 
become such a strong trend that many new findings have been made that advance not only 
the understanding of the biology of autophagy, but also the understanding of diseases in 
various organ systems. This is no exception for the liver, in which autophagy is known to be 
important for the cellular homeostasis, for the metabolism regulation, and for the 
pathogenesis of liver diseases ranging from simple steatosis to advanced hepatocellular 
carcinoma (HCC). This issue of Liver Research is dedicated to the recent advances in the 
understanding of the function and role of autophagy in liver diseases. The editors are hoping 
that organizing such an issue contributed by leading experts in the field will promote the 
study of autophagy in the liver and in turn find better ways to treat liver-related illness.
Notably, observations of autophagy in the hepatocyte were among the earliest studies of this 
fundamental, evolutionarily conserved phenomenon.1,2 The liver has been an essential 
mammalian system for the study of autophagy. In the pre-yeast days, many of the important 
findings regarding autophagy, such as the morphology of autophagosomes, the relationship 
with protein degradation, the important role of autophagy in metabolism, were made in the 
liver system.2,3 With the introduction of yeast genetics in the early 1990s, autophagy 
research entered the molecular times.4 At present more than 40 genes in the core autophagy 
pathways, known as the autophagy-related (Atg) genes, have been reported, many of which 
are evolutionarily conserved.4 The discovery of these genes has provided the molecular 
maps for the mechanisms by which autophagy is activated and executed. In addition, they 
are critical tools to study the role of autophagy in the pathogenesis of many diseases.
The articles by Khambu et al.,5 Hikita et al.,6 and Ma et al.7 reviewed the concept and the 
basic machinery of autophagy with an emphasis on different steps. In addition, the major 
signaling pathways of mammalian target of rapamycin (mTOR) and AMP-activated protein 
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kinase (AMPK) are discussed for their roles in regulating autophagy activation. These 
pathways are often disturbed in the disease context, such as in the fatty liver disease (FLD) 
and stress conditions, thus can be part of the molecular changes along with autophagy 
dysfunction, contributing to the pathogenesis.
Our understanding of autophagy has also become more accurate and defined at the 
subcellular level. The autophagy process is better categorized as the selective and non-
selective ones. In the early days, autophagy is considered to be non-selective, engulfing all 
types of cytosolic components randomly. We now know that this may not be the case under a 
majority of conditions. Instead, selective removal of a specific type of organelle may be a 
more routine process than previously thought. Thus specific terminologies for removing a 
particular type of organelle have evolved, such as lipophagy for removing lipid droplets, 
mitophagy for removing mitochondria and endoplasmic reticulum (ER)-phagy for removing 
ER. Specific adaptor molecules are involved in the recognition of the targets by the 
autophagosomes (see the review by Khambu et al.5 and Ma et al.7).
2. Lipophagy and FLD
The review by Khambu et al.5 summarized the role of autophagy in FLD. FLD is now the 
most common liver disease, which can be caused by alcohols (alcoholic fatty liver disease 
(AFLD)), or other non-alcoholic factors (non-alcoholic fatty liver disease (NAFLD)), among 
which the most common one is the uptake of superfluous nutrients. The early and common 
presentation of FLD is the benign hepatic steatosis, which can progress to steatohepatitis in a 
sub-population of patients. Autophagy may play an important role in the early stage of FLD 
by removing lipid droplets, a process known as lipophagy. In alcoholic liver disease, 
autophagy may also be important in removing damaged mitochondria via mitophagy, thus 
reducing cellular injury.
Autophagy can be upregulated by acute alcohol treatment,8 but can be suppressed in chronic 
alcoholic condition.9,10 Autophagy can be rapidly suppressed in mice fed with a high fat 
diet.11 Both the reviews by Khambu et al.5 and Hikita et al.6 have summarized these findings 
in different aspects. Notably, autophagy dysfunction may promote apoptosis, a key step in 
the progression of benign steatosis to steatohepatitis. Promoting autophagy 
pharmacologically can improve, whereas inhibition of autophagy can exacerbate, the liver 
injury.9
There are several potential mechanisms that may explain the suppression of autophagy in 
NAFLD. One is at the initiation stage, in which the activation of mTOR can suppress 
autophagy activation via the phosphorylation of unc-51 like autophagy activating kinase 1 
(ULK1), and suppress autophagy degradation via the phosphorylation of transcription factor 
EB (TFEB).12 TFEB is a master control gene for lysosome biogenesis and lysosomal 
function, which paradoxically supports mTOR activation.13 This mTOR-TFEB regulatory 
loop can dynamically impact the disease progression in NAFLD.11 These signaling 
components are reviewed in the article by Khambu et al.5
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The other key point where autophagy may be arrested in FLD is the step of the fusion of the 
autophagosome with the lysosome. This was briefly discussed in Khambu et al,5 but is 
extensively discussed in the review by Hikita et al.6 Here, the article summarized the recent 
understanding of the molecular components involved in the autophagosome-lysosome 
fusion. Furthermore the authors tried to examine the potential involvement of the molecular 
changes in liver diseases, with a particular emphasis on a molecule known as Rubicon. 
Rubicon is a part of beclin-1 complex and is known to be inhibitory on autophagy. Rubicon 
can thus suppress the autophagosome-lysosome fusion. The role of Rubicon in NAFLD-
induced liver injury was a key discovery from the authors’ laboratory, which suggests that it 
may be suitable for future interventions to rescue autophagy activity in NAFLD.
3. Mitophagy, aging and ethanol- or ischemia/reperfusion (I/R)-induced 
injury
As indicated above mitophagy could be important in controlling mitochondrial damage in 
the alcoholic liver diseases. In fact, mitophagy could occur in many contexts. John 
Lemasters is a leading expert in mitophagy biology, who first coined the mitophagy term.14 
The review by him and his colleague has defined the mitophagy in three categories, each 
with distinct molecular mechanisms, structure features and biochemical alterations.15 The 
pathophysiological relevance of mitophagy is particularly discussed in the context of 
ethanol-induced liver toxicity, in which ethanol causes mitochondrial depolarization and 
type 2 mitophagy. Type 2 mitophagy depends on PTEN-induced kinase 1 (PINK1)/Parkin. It 
may play roles in reducing ethanol-induced cellular injury. But it may also be important for 
supporting chronic hepatitis viral infection (see below and Khan et al.,16 2018).
Mitophagy in I/R injury is also critically important for the recovery of hepatocytes after the 
injury. The review by Lee and Kim17 discussed the importance of SIRT1-MFN2 pathway in 
this process. The key element is the influence of aging and the corresponding role of 
autophagy in the process. The authors noted the age-related difference in the autophagy 
pathway and therefore the ability of mitochondrial quality control and hepatocyte survival 
after I/R injury. This review covered several topics that cross different areas of autophagy, 
aging, mitochondrial biology and I/R-injury.
4. ER-phagy and ER biology in lipid metabolism and viral infection
Another great example of selective autophagy, perhaps more seen in the hepatocytes than in 
other cells, is ER-phagy, or selective removal of ER by autophagy. The review by Ma et al.7 
has timely summarized the recent progresses in this area.
ER is a complicated system, participating in many cellular functions related to protein 
synthesis, lipids and steroid metabolism, calcium regulation and drug metabolism. ER is also 
a favorite site targeted by virus, such as the hepatitis virus. When ER function is disturbed, 
ER stress arises, which can trigger multiple pathways, known as unfolded protein response 
(UPR). UPR can also activate autophagy.18
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ER itself could be subjected to autophagic removal. One of the key functions of ER in the 
hepatocyte is related to drug metabolism as the cytochrome p450 system is mostly located in 
the smooth ER.Drug administration can stimulate the expression of cytochrome p450 
enzymes and the proliferation of ER. The ER network shrinks after drug withdrawal and 
much of the ER structure could be removed by autophagosomes. Ma et al.7 systemically 
reviewed ER-phagy in the yeast and in the mammalian cells. They have discussed a number 
of adaptor molecules, or selective receptors, for ER to be recognized by the autophagosomal 
membranes, and for their potential involvement in liver diseases.
Elimination of intracellular pathogens by autophagy is known as xenophagy. This, however, 
is not straightforward. Pathogens often have complex interactions with the cellular 
machinery, in which they may evade or even hijack the autophagy system. Hepatitis B virus 
(HBV) and hepatitis C virus (HCV) can both fool the cell to activate and to use autophagy 
for their benefits during their replications. This allows persistent and chronic viral infection. 
Khan et al.16 have provided a quite comprehensive review on the role of HBV and HCV in 
autophagy induction and in turn the role of autophagy in the pathological effects of these 
viruses in the liver. One way HBV and HCV can induce autophagy is via ER stress and 
UPR. Other mechanisms, including those involving the mitochondria or the Golgi complex 
are also discussed. A broad scope of literature have been reviewed and different studies, 
some of which are controversial, are presented in a nicely arranged fashion to help the 
readers to understand the issues and the mechanisms involved.
5. Autophagy, cell death and hepatic cancer development
In normal cells, autophagy may act as a tumor suppressor by removing damaging organelles, 
such as mitochondria, and reducing oxidative stress, which can induce tumorigenic 
mutations.19 Autophagy may also inhibit hepatic tumor development by inhibiting the 
release of a damage-associated molecular pattern (DAMP) molecule, high-mobility group 
box 1 (HMGB1), which promotes tumor growth.20 However, in tumor cells, which are often 
under various types of stress, some of which are caused by interventional therapy, autophagy 
can serve as a survival strategy to protect tumor cells.21 Interestingly, a recent study has 
shown that autophagy can be important for the development of hepatic cancer stem cells by 
preventing mitochondrial p53 from inhibiting the transcription of a stemness factor, 
NANOG.22 Finally, cell death depending on the autophagy machinery has been reported and 
known as autophagic death.23 Thus the role of autophagy in hepatic cancer development 
could be multiple, depending on the stage of tumorigenesis, and depending on the internal 
and external driving forces. In the article by Pang and Liu,24 they discussed autophagic cell 
death in the context of HCC. They discussed several possible mechanisms, by which 
autophagy is linked to cell death. In particular, the authors proposed that damage-regulated 
autophagy modulator (DRAM)-mediated mitophagy is linked to a new type of autophagic 
cell death. A potential significance of this type of cell death is that they may be construed as 
a new way to treat HCC, e.g., by certain herbal medicines.
Overall, reading through these reviews, one may find that removal of certain subcellular 
materials, such as lipid droplets, damaged mitochondria or expanded ER, is important to 
keep hepatocytes healthy and to reduce damages in the case of FLD or I/R injury, or to 
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reduce tumorigenesis. In this case one may want to maintain and even stimulate the 
autophagy function. On the other hand, autophagy function can be taken over by cells or 
virus for their advantage to maintain survival and to proliferate. When survival autophagy 
occurs in the tumor cells or virus-infected cells one may not want to keep autophagy 
function. Autophagy can thus be a double-edged sword. Manipulations of autophagy for 
therapeutic purposes have to consider all these factors and have to be context-dependent in 
order to be effective.
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